Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report

While standard treatment has shown efficacy in patients with breast cancer gene (BRCA) mutations, recurrence rates are high and additional effective therapies are needed. Olaparib, a poly adenosine diphosphate–ribose polymerase (PARP) inhibitor, approved for the treatment of metastatic germline BRCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Caputo, Roberta, Pagliuca, Martina, Pensabene, Matilde, Parola, Sara, De Laurentiis, Michelino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438988/
https://www.ncbi.nlm.nih.gov/pubmed/37601649
http://dx.doi.org/10.3389/fonc.2023.1214660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438988/
https://www.ncbi.nlm.nih.gov/pubmed/37601649
http://dx.doi.org/10.3389/fonc.2023.1214660

Ejemplares similares